ProMetic Life Sciences Inc.

259 articles about ProMetic Life Sciences Inc.

• ProMetic Life Sci Completes The Filing Of Its Plasminogen Biologics License Application ("BLA") With The U.S. FDA

  4/5/2017

• ProMetic Life Sci Reports Its 2016 Fourth Quarter And Year End Highlights And Financial Results

  3/31/2017

• ProMetic Life Sci To Report Its Fourth Quarter And Year-End 2016 Financial Results And Hold Conference Call / Webcast

  3/23/2017

• FDA Grants Orphan Drug Designation To ProMetic Life Sci's PBI-4050 Drug For The Treatment Of Alström Syndrome

  3/3/2017

• ProMetic Life Sci's PBI-4050 Continues To Demonstrate Early Evidence Of Efficacy Following Completion Of Idiopathic Pulmonary Fibrosis Phase II Clinical Trial

  2/22/2017

• ProMetic Life Sci Release: Company's PBI-4050 Receives Promising Innovative Medicine Designation From The UK MHRA For The Treatment Of Alström Syndrome

  1/24/2017

• ProMetic Life Sci Releaase: European Commission (EC) Grants Orphan Drug Designation To Company's PBI-4050 Drug For The Treatment Of Alström Syndrome

  1/18/2017

• ProMetic Life Sci Initiates Rolling Submission Of Its Biologics License Application ("BLA") For Plasminogen With U.S. FDA

  12/19/2016

• ProMetic Life Sci Comments On Unusual Trading Activity

  12/19/2016

• ProMetic Life Sci Responds To False Market Data Report Regarding Insider Selling

  12/8/2016

• ProMetic Life Sci's PBI-4050 Demonstrates Early Evidence Of Efficacy In Its Idiopathic Pulmonary Fibrosis ("IPF") Phase 2 Clinical Trial

  11/17/2016

• ProMetic Life Sci Receives Clearance From Health Canada To Proceed With Its PBI-4050 Placebo-Controlled Phase 2 Clinical Trial In Patients With Metabolic Syndrome And Type 2 Diabetes

  11/16/2016

• ProMetic Life Sci Reports Third Quarter 2016 Highlights And Financial Results

  11/15/2016

• ProMetic Life Sci's PBI-4050 Shown To Reduce Pulmonary Hypertension And Lung Remodeling And To Improve Right Ventricular Function In Heart Failure With Reduced Ejection Fraction ("HFrEF")

  11/14/2016

• Telesta Announces Final Court Approval Of Plan Of Arrangement With ProMetic Life Sci

  10/31/2016

• Telesta Announces Closing Of Arrangement With ProMetic Life Sci

  10/31/2016

• ProMetic Life Sci's Plasminogen Meets Primary And Secondary End Points In Pivotal Phase 2/3 Trial

  10/26/2016

• Telesta Shareholders Approve Plan Of Arrangement With ProMetic Life Sci

  10/25/2016

• ProMetic Life Sci's PBI-4050 Meets Primary And Secondary End Points In Metabolic Syndrome And Type 2 Diabetes Phase 2 Clinical Trial

  10/20/2016

• ProMetic Life Sci's PBI-4050 Significantly Reduces Liver Fibrosis In Patients With Alström Syndrome

  10/12/2016